Institutional Investors Bet Big on BillionToOne as Molecular Diagnostics Sector Gains Momentum
A significant shift in the molecular diagnostics landscape has caught the attention of market analysts this week. BillionToOne, a company specializing in
by 
Josh Weiner
Josh Weiner